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Mesenchymal stromal cells (MSCs) exert immunosuppressive effects on immune cells 
including dendritic cells (DCs). However, many details of the bidirectional interaction of 
MSCs with DCs are still unsolved and information on key molecules by which DCs can 
modulate MSC functions is limited. Here, we report that osteopontin (OPN), a cytokine 
involved in homeostatic and pathophysiologic responses, is constitutively expressed 
by DCs and regulated in the DC/MSC cocultures depending on the activation state 
of MSCs. Resting MSCs promoted OPN production, whereas the production of OPN 
was suppressed when MSCs were activated by proinflammatory cytokines (i.e., TNF-α, 
IL-6, and IL-1β). OPN induction required cell-to-cell contact, mediated at least in 
part, by β1 integrin (CD29). Conversely, activated MSCs inhibited the release of OPN 
via the production of soluble factors with a major role played by Prostaglandin E2 
(PGE2). Accordingly, pretreatment with indomethacin significantly abrogated the MSC-
mediated suppression of OPN while the direct addition of exogenous PGE2 inhibited 
OPN production by DCs. Furthermore, DC-conditioned medium promoted osteogenic 
differentiation of MSCs with a concomitant inhibition of adipogenesis. These effects 
were paralleled by the repression of the adipogenic markers PPARγ, adiponectin, and 
FABP4, and induction of the osteogenic markers alkaline phosphatase, RUNX2, and of 
the bone-anabolic chemokine CCL5. Notably, blocking OPN activity with RGD peptides 
or with an antibody against CD29, one of the OPN receptors, prevented the effects of 
DC-conditioned medium on MSC differentiation and CCL5 induction. Because MSCs 
have a key role in maintenance of bone marrow (BM) hematopoietic stem cell niche 
through reciprocal regulation with immune cells, we investigated the possible MSC/DC 
interaction in human BM by immunohistochemistry. Although DCs (CD1c+) are a small 
percentage of BM cells, we demonstrated colocalization of CD271+ MSCs with CD1c+ 
DCs in normal and myelodysplastic BM. OPN reactivity was observed in occasional 
CD1c+ cells in the proximity of CD271+ MSCs. Altogether, these results candidate OPN 
as a signal modulated by MSCs according to their activation status and involved in DC 
regulation of MSC differentiation.
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inTrODUcTiOn
Mesenchymal stromal cells (MSCs) are non-hematopoietic 
precursors able to self-renew, which differentiate into multiple 
cell lineages including osteoblasts, chondrocytes, and adipocytes 
(1). Originally isolated from the bone marrow (BM), MSCs are 
present in multiple tissues including adipose tissue and umbilical 
cord blood (2). Beside their regenerative capacity, MSCs possess 
immunomodulatory properties (3, 4) raising their importance 
as a potential therapeutic strategy in immune-related diseases 
(5, 6). Indeed, MSCs suppress the proliferation of T cells and the 
differentiation/maturation of antigen-presenting cells. They also 
induce regulatory T cells that further suppress immune responses 
(7–9). MSCs were reported to inhibit the effector functions of 
other immune cells, including B and NK  cells by a cell-to-cell 
contact mechanism and the secretion of soluble factors (10, 11).
The immunomodulatory action of MSCs apparently depends 
on the local microenvironment. At the sites of inflammation, 
IFN-γ and TNF-α are key cytokines in licensing MSCs to become 
immunosuppressive. On the other hand, in the absence of inflam-
mation, MSCs can stimulate immune responses (4). For example, 
despite their ability to inhibit the proliferation of activated T cells, 
MSCs can support T cells as well as neutrophils survival in the 
BM (12–14). While MSCs can modify immune cell behavior, a 
reciprocal influence of immune cells on MSC functions was also 
reported with a role of immune cells in MSC homeostasis and in 
the process of tissue regeneration (15).
Dendritic cells are professional antigen-presenting cells 
that play a critical role in the induction of both immunity and 
tolerance (16–18). Given the pivotal role of DCs in immunity, 
the influence of MSCs on DC functions was investigated in 
several studies (19). MSCs were reported to significantly impair 
DC differentiation and maturation and to inhibit the secretion of 
several cytokines, such as TNF-α and IL-12 (20–22). Coherently 
with an overall anti-inflammatory effect, MSCs colocalize with 
DCs at the sites of inflammation (23). However, MSCs also colo-
calize with DCs in the perivascular areas of healthy adipose tissue 
where DCs concur to tissue homeostasis (24). In addition, MSCs 
and DCs colocalize in the BM in perisinusoidal areas (25, 26). 
Thus, the interplay between DCs and MSCs might also happen 
in homeostatic conditions.
We and others have previously shown that DCs are a prominent 
source of osteopontin (OPN) (27, 28), a multifunctional protein 
that influences both immune and non immune cells. OPN func-
tions through the interaction with multiple cell surface receptors 
known to be expressed by MSCs, such as various integrins and 
CD44 (29, 30). Under physiological conditions, OPN expression 
is restricted to certain tissues including bone, kidney, and intestine 
where it accomplishes a physiologic control of bone remodeling 
and hematopoietic stem cell location and proliferation (31, 32). 
Conversely, in inflamed and injured tissues, OPN is strongly 
upregulated and is involved in the pathogenesis of various inflam-
matory disorders, such as autoimmune disorders, several types of 
cancer, and cardiovascular diseases (29, 33, 34). Indeed, OPN was 
shown to regulate innate and adaptive immune responses and is 
generally classified as a proinflammatory cytokine even though 
it also has antinflammatory actions (35, 36). In addition, OPN 
regulates MSC migration and differentiation to promote wound 
healing (37). These OPN properties prompted us to investigate 
the role of OPN in the interplay between MSCs and DCs in 
both homeostatic and inflammatory conditions. The results here 
reported show that OPN is modulated in the DC/MSC crosstalk 
and plays a role in the MSC differentiation mediated by DCs.
MaTerials anD MeThODs
generation of human Msc From adipose 
Tissue
Human adipose tissues were collected by lipoaspiration from 
healthy donors after written consent and according with the 
Declaration of Helsinki and with the local ethic committee 
(Comitato Etico Interaziendale A.O.U. Città della Salute e della 
Scienza di Torino—A.O. Ordine Mauriziano—ASL TO1, number 
0009806). MSCs were obtained after a monolayer expansion of 
the stromal vascular fraction (SVF) isolated from adipose tissue 
samples as previously described (38, 39). Briefly, the SVF cells were 
seeded in T25 flasks and cultured in DMEM with 10% FBS, 2 mM 
glutamine, and 1% antibiotics (Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA) and the medium was replaced to eliminate 
non-adherent cells after 24 h. Then MSCs were cultured for 2–3 
passages, and their phenotype was analyzed by flow cytometry. 
MSCs were identified as CD73, CD90, and CD105 positive cells 
and negative for the CD11b, CD34, and CD45 expression.
Monocyte-Derived Dc Preparation
Monocytes were isolated from peripheral blood mononuclear cells 
obtained from healthy donor buffy coats (through the courtesy 
of the S.C. Centro Produzione e Validazione Emocomponenti, 
Torino) by immunomagnetic selection with CD14 microbeads 
(MACS monocyte isolation kit from Miltenyi Biotec, Bergisch 
Gladbach, Germany). This procedure yields an at least 98% pure 
monocyte population, as assessed by fluorescence-activated cell 
sorter analysis (FACSCalibur, BD Biosciences, Franklin Lakes, 
NJ, USA). To obtain monocyte-derived DCs, monocytes were 
cultured for 5 days at 106 cells/ml in RPMI 1640 medium (Gibco) 
containing 10% FCS in the presence of GM-CSF (50 ng/ml) and 
IL-4 (20 ng/ml) (both from PeproTech, Rocky Hill, NJ, USA).
Preparation of conditioned Media
To prepare conditioned medium from MSCs, cells at 0.2 × 106   
cells/ml in RPMI supplemented with 10% FCS were left untreated, 
stimulated for 24 h with IL-1β (25 ng/ml), IL-6 (20 ng/ml), and 
TNF-α (50 ng/ml) (all from PeproTech) (40) or with PBMCs at 
a ratio PBMC:MSC 5:1 for 5 days. In some experiments, treated 
MSCs were also treated with 10  µM of indomethacin (IDM) 
(Cayman Chemical, Ann Arbor, MI, USA). Conditioned media 
were obtained by centrifugation of MSCs (MSC-CM), to discard 
cells and debris, and different concentrations of CM were used 
to treat DCs.
To prepare conditioned medium from DCs (DC-CM) or 
DC/MSC coculture (ratio 5:1), DCs were extensively washed 
and cultured for further 48 h at 1 × 106 cells/ml in RPMI 10% 
FBS without GM-CSF and IL-4. After centrifugation to discard 
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cells and debris, the conditioned media obtained were aliquoted, 
stored at −20°C and used at different concentrations to induce 
MSC differentiation and to evaluate CCL5 production by MSCs.
cell cultures
Dendritic cells cultured at 1 × 106 cells/ml were stimulated for 24 h 
with different concentrations of prostaglandin E2 (PGE2) (10−9 
to 10−5  M) (Sigma-Aldrich S.r.l. Milan, Italy), 10  µM butaprost 
(EP2 agonist), 10 µM misoprostol (EP2/EP3/EP4 agonist), 10 µM 
sulprostone (EP1/EP3 agonist) (all from Cayman Chemical), 
50 µM Dioctanoyl-cAMP (d-cAMP) (Calbiochem, Merck KGaA, 
Darmstadt, Germania), or 50  µM forskolin (FSK) (Alexis Bio-
chemicals, San Diego, CA, USA). In some experiments, cells at 
1 × 106 cells/ml were untreated or treated with different concentra-
tions of MSC-CM previously prepared as indicated above.
Depending on the experiments, MSCs and DCs were cultured 
in contact or separated using transwell inserts with 0.4  µm 
inserts (Corning Costar, Sigma-Aldrich). MSCs, unstimulated 
or in the presence of IL-1β (25  ng/ml), IL-6 (20  ng/ml), and 
TNF-α (50 ng/ml), were plated at the bottom of 24-well plates 
at a seeding density of 0.05 × 106 cells in 0.5 ml and DCs plated 
in transwell insert at 0.25 × 106 cells/0.1 ml. The same ratios and 
volumes were used for direct contact cultures. MSCs and DCs 
alone were cultured and stimulated using the same number of 
cells/volume of the coculture. Supernatants were collected after 
24 or 48 h. Where specified, DCs, MSCs, or the direct coculture 
of DC/MSC were treated for 48  h with 10  µg/ml Arg-Gly-Asp 
(RGD) (Sigma-Aldrich), 2  µg/ml cilengitide (CIL) (MedChem 
Express, NJ, USA), or the scrambled peptide Arg-Gly-Glu (RGE) 
(Sigma-Aldrich). MSCs were also pre-treated for 1 h with spe-
cific antibodies against CD44 (clone 5F12; Lifespan Biosciences, 
Inc., Nottingham, United Kingdom), CD29 (clone P5D2; R&D 
Systems, Inc., MN, USA), CD54 (clone HCD54; Biolegend, San 
Diego, CA, USA), and CD58 (clone TS2/9; Biolegend) or the cor-
responding isotype control antibody at 10 µg/ml (R&D Systems) 
and then cocultured with DCs (ratio DC/MSC 5:1) for 48 h.
In some experiments, MSCs alone were cultured at 
0.1 × 106 cells/well and treated with different concentrations of 
previously prepared DC-CM for 24 and 48 h.
Flow cytometric analysis
Mesenchymal stromal cells were analyzed by flow cytometry with 
a FACSCalibur equipped with CellQuest software (BD Biosciences, 
Milano, Italy) using the following antibodies: anti CD44-PE and 
anti CD29-PE and the corresponding isotype control antibodies 
(all purchased from Biolegend).
real-Time Pcr
Total MSC-RNA isolated with the Qiagen RNeasy mini kit was 
treated with DNase I (Qiagen, Hilden, Germany) and retro-
transcribed into cDNA by using the iScript cDNA Synthesis Kit 
(Bio-Rad Laboratories Inc., Hercules, CA, USA). Gene specific 
primers were:
Adiponectin (ADIPOQ) (sense, 5′-AGGGTGAGAAAGGAGA 
TCC-3′; antisense, 5′-GGCATGTTGGGGATAGTAA-3′), FABP4 
(sense, 5′-TGGTTGATTTTCCATCCCAT-3′; antisense, 5′-TACT 
GGGCCAGGAATTTGAC-3′), PPARγ (sense, 5′-CCTATTGAC 
CCAGAAAGCGATT-3′; antisense, 5′-CATTACGGAGAGATCC 
ACGGA-3′), alkaline phosphatase (ALP) (sense, 5′-AGCACTCC 
CACTTCATCTGGAA-3′; antisense, 5′-GAGACCCAATAGGTA 
GTCCACATTG-3′), RUNX2 (sense, 5′-AGAAGGCACAGACAG 
AAGCTTGA-3′; antisense, 5′-AGGAATGCGCCCTAAATCAC 
T-3′), CCL5 (sense, 5′-CCTCATTGCTACTGCCCTCT-3′; anti-
sense, 5′-ACGACTGCTGGGTTGGAGCACTT-3′), RPL13A 
(sense, 5′-CATAGGAAGCTGGGAGCAAG-3′; antisense, 5′-GC 
CCTCCAATCAGTCTTCTG-3′). The iQ™ SYBR Green Supermix 
(Bio-Rad Laboratories Inc., Segrate, MI, Italy) for quantitative 
real-time PCR was used according to manufacturer instructions. 
Reactions were run in duplicate on an iCycler Chromo4™ (Bio-
Rad Laboratories Inc.) and Opticon Monitor™ 3.0 Software and 
Genex Macro were used for data analysis (Bio-Rad Laboratories 
Inc.). Gene expression was normalized based on RPL13A mRNA 
content.
elisa
Cell-free supernatants were harvested and OPN and CCL5 
production was measured by ELISA assay (R&D Systems, 
Minneapolis, MN, USA). PGE2 production was assessed by EIA 
kit (Cayman Chemical).
adipogenic induction
Mesenchymal stromal cells were cultured with DMEM and pas-
saged twice/three times. Then, cells were seeded into 12-well plates, 
and adipogenic induction was performed using StemMACS™ 
AdipoDiff Media (Miltenyi Biotec). Cells were cultured in pres-
ence of complete adipogenic medium or with 70% AdipoDiff 
Media plus 30% DC-CM or DC/MSC-CM or 30% basal medium, 
or recombinant human OPN (1 µg/ml) (Peprotech). Medium was 
changed every 4/5 days and mRNA extraction was performed at 5 
and 12 days while lipid droplet staining was evaluated at 15 days 
of culture. In some experiments, cells cultured in presence of 
DC-CM were treated with neutralizing monoclonal antibodies 
against CD44 (clone 5F12; Lifespan Biosciences, Inc.) and CD29 
(clone P5D2; R&D Systems) or with the corresponding isotype 
control antibody at 10 µg/ml (R&D Systems).
Osteogenic induction
Mesenchymal stromal cells were seeded into 12-well plates, and 
osteogenic induction was performed using DMEM medium sup-
plemented with 50 µM ascorbic acid, 10 mM beta glycerophos-
phate, and 100  nM dexamethasone (all from Sigma-Aldrich). 
MSCs were cultured in presence of complete osteogenic medium 
or with 70% osteogenic medium plus 30% DC-CM or 30% basal 
medium, or recombinant human OPN (1 µg/ml). mRNA extrac-
tion was performed at 7 and 14 days and Alizarin staining at 14 
and 21 days.
Oil red O staining
To evaluate adipogenesis, cells were fixed in 4% paraformalde-
hyde for 10  min at RT, washed twice with distilled water, and 
incubated with 60% isopropanol for 10 min at RT. Then, solution 
was removed and cells were incubated in fresh Oil Red O (1.8 in 
60% isopropanol) (Sigma-Aldrich) for 5 min at RT. Cells were 
washed with isopropanol, and induced cells were visible as cells 
FigUre 1 | Influence of mesenchymal stromal cells (MSCs) on osteopontin 
(OPN) production by dendritic cells (DCs). (a) DCs were cultured alone or 
with MSCs (ratio DC/MSC 5:1) in the absence or in the presence of the 
proinflammatory cytokines (IL-1β, TNF-α, IL-6) for 24 h and OPN levels was 
determined in the supernatants by ELISA. Results are expressed as 
mean ± SEM of 10 independent experiments. *p < 0.05 vs. DCs alone in 
resting conditions #p < 0.05 vs. DC/MSC coculture in resting conditions and 
vs. DCs alone in presence of cytokines by Student’s t-test. (B) DCs were 
cultured without MSCs or with MSCs in contact or in transwell systems for 
24 h in resting conditions (left panel) or in presence of proinflammatory 
cytokines (right panel). Tested ratio were DC/MSC 5:1. OPN levels were 
measured by ELISA and expressed as % of OPN production by DCs alone 
set as 100% (mean ± SEM of five independent experiments). *p < 0.05 vs. 
DCs alone by Student’s t-test.
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containing consistent red deposits in vacuoles. Positive cells were 
visualized by light microscopy and photographed and the per-
centage of differentiated cells was determined by counting cells 
based on Oil Red O staining in the lipid vacuoles (adipocytes 
were counted in five random fields). Quantification of lipid 
accumulation is achieved by Oil Red O extraction by lysis (100% 
isopropanol) and gentle agitation for 10 min at room temperature. 
Following Oil Red O extraction, 150 µl are transferred to a 96-well 
plate and absorbance measured at 490 nm using a plate reader.
alizarin red s staining
The culture medium was discarded, and the cells were gently rinsed 
with PBS twice. Then, the cells were fixed with 4% paraformal-
dehyde for 10 min at room temperature. The cells were washed 
with distilled water three times and stained with 2% Alizarin red 
S (Sigma-Aldrich) for 30 min at RT. The cells were washed again 
with distilled water three times. Finally, the cells were rinsed 
with water, and the Alizarin red S staining was observed using 
a microscope. The formation of red calcium deposits is a marker 
of osteogenic differentiation. To quantify Alizarin Red S staining, 
the stained cells were incubated in 10% acetic acid for 30 min and 
absorbance was measured at 405 nm with a microplate reader.
immunohistochemistry
In order to validate our hypothesis ex vivo, we selected thirteen 
BM trephine biopsy (BMB) from the Pathology archive of the 
University of Brescia. Ten normal BMB were selected from stag-
ing biopsy, negative for lymphoma; additionally, we selected three 
cases with diagnosis of myelofibrosis, a pathological condition 
known to be associated with increased expression of CD271/
NGFR (41).
Immunohistochemistry was performed on 2 µm sections of 
formalin fixed-paraffin embedded tissue using the following 
antibodies: OPN (Polyclonal Goat IgG, R&D Systems, dilu-
tion, 1:65), CD1c (clone OTI2F4, Abcam, Cambridge, United 
Kingdom, dilution 1:300), CD14 (clone 7, Leica Microsystems, 
Wetzlar, Germany, dilution 1:50), CD38 (clone SPC32, Leica 
Microsystems, dilution 1:100), CD271/NGFR (clone 7F10, Leica 
Microsystems, kindly provided by Prof Tripodo, University of 
Palermo, Italy, dilution 1:50), E-cadherin (clone 36, Ventana 
Medical Systems, Tucson, AZ, USA, prediluted), Myeloperoxidase 
(polyclonal, Dako-Agilent Technologies Santa Clara, CA, USA, 
dilution 1:6,000). Double and triple stainings were performed as 
previously described (42).
statistical analysis
Statistical significance was determined by using non-parametric 
Student’s t-test and one-way analysis of variance, as appropriate. 
Results were analyzed by using GraphPad PRISM 5.0 software.
resUlTs
The activation state of Mscs Dictates 
OPn Production in Dc/Msc cocultures
We and others have previously shown that high levels of OPN 
are released by DCs in both resting and stimulated conditions. 
To investigate the influence of adipose tissue-derived MSCs on 
OPN production by DCs, cells were cocultured in absence or in 
the concomitant presence of TNF-α, IL-6, and IL-1β. This previ-
ously used cocktail (40) is known to activate MSCs, better than each 
cytokine alone (43). As shown in Figure 1A, DCs constitutively 
produce high levels of OPN that were further increased in the pres-
ence of proinflammatory cytokines (66 ± 16.9 vs. 136.6 ± 25.4 ng/
ml OPN with resting and stimulated DCs, respectively). On the 
contrary, resting MSCs released low amounts of OPN, as previ-
ously reported (44), and no differences were observed in activated 
conditions. However, when DCs were cocultured with MSCs (5:1 
ratio) in the absence of deliberate stimulation, the production 
of OPN strongly increased (142.5 ±  25  ng/ml). Conversely, in 
the presence of proinflammatory cytokines, OPN levels in the 
cocultures (79 ± 8.9 ng/ml) were similar to those obtained in DC 
cultures alone. Different ratios of DCs and MSCs derived from 
adipose tissue or BM were tested and the maximal effect was 
observed at the DC/MSC ratio of 5:1 independently of the origin 
of MSCs (not shown); therefore, the DC/MSC 5:1 ratio with MSCs 
purified from adipose tissue was selected for further studies.
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To investigate the mechanisms responsible for MSC-mediated 
regulation of OPN production, DCs and MSCs were cultured 
either in contact or in transwell conditions. As depicted in 
Figure 1B, the OPN upregulation was prevented when unstimu-
lated MSCs and DCs were physically separated, implicating a 
prominent role of cell–cell contact in the process. In contrast, 
OPN suppression remained fully evident in the transwell co-
cultures of activated MSCs and DCs, suggesting that inhibition 
was mediated by soluble factors.
Mechanisms involved in the regulation  
of OPn Production in Dc/Msc cocultures
Given the necessity for DC/MSC contact for the induction of 
OPN in resting conditions, the requirement of adhesion mol-
ecules was investigated. Blocking of CD44, CD54, and CD58 by 
MSC pretreatment with neutralizing antibodies did not affect 
OPN production. On the contrary, a moderate but statistically 
significant reduction of OPN levels was observed blocking CD29 
(Figure 2A).
In order to investigate the influence of soluble factors in 
OPN inhibition in stimulated conditions, DCs were treated with 
conditioned medium of MSCs unstimulated or activated with 
TNF-α, IL-6, and IL-1β. Conditioned medium of activated MSCs, 
but not of control MSCs, was able to reduce in a dose-dependent 
manner the production of OPN by DCs (Figure  2B). Because 
of the documented immunosuppressive role of PGE2 produced 
by MSCs (22, 45), the possible involvement of this eicosanoid 
was investigated. Figure 2C shows that, as previously reported 
(46, 47), also in our culture conditions high levels of PGE2 are 
produced by MSCs activated with proinflammatory cytokines 
or cocultured with PBMCs. Consistently with this result, con-
ditioned medium from MSCs activated in the presence of IDM, 
an inhibitor of cyclooxigenase-1, failed to reduce OPN in DCs 
(Figure  2D). Furthermore, treatment of DCs with exogenous 
PGE2 (10−9 to 10−5  M) led to a dose-dependent inhibition of 
OPN production (Figure 2E, left panel). Figure 2E (right panel) 
shows that by the use of receptor antagonists EP2 and EP4 were 
identified as the receptors responsible for PGE2-mediated OPN 
production. Consistent with previous finding that the EP2/EP4 
activation pathway is coupled with an increase in cAMP produc-
tion, both d-cAMP and FSK suppressed OPN expression in DCs 
(Figure 2E, right panel).
OPn secreted by Dcs regulates 
adipogenic and Osteogenic  
Differentiation of Mscs
The possible functional effect of OPN regulation observed in 
MSC/DC cocultures on MSC differentiation was thus investi-
gated. First, MSCs were induced to differentiate into adipocytes 
in the presence of resting DC-derived conditioned medium 
(DC-CM). Analysis of lipid droplet production detected by Oil 
Red O showed fewer lipid droplets in the cytoplasm of adipo-
cytes treated with DC-CM for 15  days, compared to control 
cells. By microscopic evaluation, the percentage of adipocytes 
was 14 ± 2.5 vs. 54.4 ± 13.6% in presence of DC-CM or control 
medium, respectively. Compared to DC-CM, DC/MSC-CM did 
not differ significantly in the adipogenesis inhibition (the adipo-
cytes percentage was 15.3 ± 1.7% with DC-CM vs. 12.4 ± 2.0% 
with DC/MSC-CM in two independent experiments). The results 
obtained with DC-CM were further supported by quantification 
of the solubilized stain, with 1.8-fold lower absorbance values 
with DC-CM vs. control-differentiated MSCs (Figure  3A). In 
agreement with this result, it was observed in MSCs differentiated 
in presence of DC-CM, a reduction in the expression of mark-
ers normally associated with adipogenesis, such as adiponectin 
(ADIPOQ), FABP4, and PPARγ, assessed by RT-PCR at 12 days 
of culture (Figure  3B). Since MSCs express CD29 and CD44, 
two receptors involved in OPN signaling (Figure 3C, left panel), 
MSCs were induced to differentiate into adipocytes in presence 
of human recombinant OPN (rhOPN) or of DC-CM in the 
presence of the neutralizing antibodies for CD29 and CD44. 
Figure  3C (right panel) shows that, as expected, recombinant 
OPN and DC-CM reduced the expression of the adipose-specific 
genes ADIPOQ and FABP4 and that blocking of integrin β1 
(antiCD29 moAb) reverted the inhibitory effect of DC-CM. No 
involvement of CD44 was apparently observed.
In parallel, MSCs were also induced to differentiate into osteo-
blasts in the presence of DC-CM. As shown in Figure 4A, a strong 
intensity staining with Alizarin Red S could be detected at 14 and 
21  days in presence of DC-CM compared to control medium. 
Alizarin Red stain quantification confirmed that in presence of 
DC-CM osteoblast differentiation was approximately 1.6- and 
2.8-fold higher than in control cells at 14- and 21-day culture, 
respectively (Figure  4B). As expected based on these results, 
the mRNA expression of osteo-specific genes, such as the ALP 
and Runt-related transcription factor 2(RUNX2), were increased 
in cells cultured in the presence of DC-CM or rhOPN at 7 and 
14 days. Moreover, the expression of CCL5, a chemokine recently 
shown to be involved in the induction of osteogenesis of MSCs 
(48) was also significantly higher in MSCs differentiated with 
DC-CM (at 7 and 14 days) or with rhOPN (at 7 days) compared 
to control cells (Figure 4C). Taken together, our results strongly 
suggest that OPN secreted from DCs skew MSC differentiation 
to osteogenesis.
OPn regulates ccl5 Production  
in the Dc/Msc cocoultures
CCL5 upregulation observed during osteogenesis in the presence 
of DC conditioned medium prompted us to further explore CCL5 
production in DC-MSC crosstalk. As shown in Figure 5A (left 
panel), CCL5 levels in the DC/MSC coculture were significantly 
higher compared to DCs and MSCs cultured alone (about sixfold 
increase with respect to MSCs alone and about 10-fold increase 
with respect to DCs alone), similarly to what observed for the 
production of OPN (Figure 5A, right panel). To demonstrate a 
possible role of OPN in CCL5 production, MSCs were stimulated 
with DC-CM and CCL5 was quantified. In the presence of 
DC-CM, CCL5 levels augmented in a concentration dependent 
manner at 24 and 48 h stimulation with the peak attained at 48 h 
(Figure 5B). Moreover, inhibition of RGD integrins, a family of 
OPN receptors, with two different integrin antagonists Arg-Gly-
Asp (RGD) and Cilengitide (CIL), significantly reduced CCL5 
FigUre 2 | Mechanisms involved in the regulation of osteopontin (OPN) production in DC/mesenchymal stromal cells (MSC) cocultures. (a) MSCs were pretreated 
for 1 h with the specific neutralizing antibodies against CD44, CD29, CD54, and CD58 or the corresponding isotype ctrl (mIgG1) and then cultured with dendritic 
cells (DCs) (ratio DC/MSC 5:1) for 48 h. Supernatants were collected and tested for OPN production by ELISA. OPN levels are expressed as % of OPN production 
in DC/MSC alone set as 100% (mean ± SEM of four independent experiments). *p < 0.05 vs. DC/MSC coculture untreated by Student’s t-test. (B) DCs were 
cultured alone or with the addition of conditioned medium from MSCs unstimulated (25% v/v) or with different concentrations of conditioned medium from MSCs 
activated for 24 h with proinflammatory cytokines (MSC-CM or cytokines MSC-CM). Supernatants were collected after 24 h and tested for OPN production by 
ELISA and expressed as % of OPN production by DCs alone set as 100%. *p < 0.05 vs. DCs alone by one-way ANOVA followed by Tukey’s Multiple Comparison 
Test. (c) PGE2 levels were measured by ELISA in supernatants from MSCs unstimulated or cocultured for 5 days with PBMCs (PBMC/MSC) or untreated or treated 
for 24 h with proinflammatory cytokines (cytokines MSC). Results are representative of four and three experiments, respectively. *p < 0.05 vs. MSC unstimulated by 
Student’s t-test. (D) DCs were cultured alone (no CM) or in the presence of supernatants from MSCs stimulated with proinflammatory cytokines for 24 h (cytokines 
MSC-CM) or co-cultured with PBMC (ratio PBMC/MSC 5:1) for 5 days (PBMC/MSC-CM). MSC stimulation was performed with or without indomethacin (IDM). After 
24 h, DC supernatants were collected and tested for OPN production by ELISA. Results are expressed as % of OPN production by DCs alone set as 100% 
(mean ± SEM of six independent experiments). *p < 0.05 vs. DCs alone (no CM); #p < 0.05 vs. MSC-CM without IDM (ctrl) by one-way ANOVA followed by Tukey’s 
Multiple Comparison Test. (e) DCs were stimulated with different concentrations of PGE2. Supernatants were harvested 24 h later and subjected to OPN ELISA (left 
panel) (mean ± SEM of six independent experiments). DCs were stimulated with Sulprostone (EP1/3 agonist), Butaprost (EP2 agonist), Misoprostol (EP2/3/4 
agonist), PGE2, Forskolin (FSK), and dcAMP. After 24 h, supernatants were collected and tested for OPN by ELISA (right panel) (mean ± SEM of four independent 
experiments). Results are expressed as % of OPN production by DCs alone set as 100%; *p < 0.05 vs. DCs alone by one-way ANOVA followed by Dunnett’s 
Multiple Comparison Test.
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FigUre 3 | DC-conditioned medium inhibits mesenchymal stromal cells (MSC) differentiation into adipocytes through osteopontin release. (a) MSCs were cultured 
for 15 days in adipocyte differentiation medium in the presence of 30% DC-CM or RPMI (control condition, ctrl) and stained with Oil Red O to reveal lipid droplets 
(original magnification 5×) (left panel). Adipocytes were counted in five random fields from one representative well per group (middle panel) and Oil Red O extracted 
with isopropanol was measured at optical density 490 (right panel) (mean ± SEM of four independent wells). *p < 0.05 vs. ctrl by Student’s t-test. (B) The mRNA 
levels of ADIPOQ, FABP4, and PPARγ2 were analyzed by real-time PCR at days 5 and 12 of culture. Data were shown as means ± SEM (n = 3). *p < 0.05 vs. ctrl 
by Student’s t-test. (c) MSCs were examined for the expression of CD29 and CD44 by flow cytometry (gray area, isotype control; white area, specific antibody). 
MSCs were induced by adipogenic differentiation medium in control condition, with rhOPN or DC-CM in the presence or the absence of the indicated antibodies. 
Relative mRNA expression of ADIPOQ and FABP4 was measured by real-time PCR on day 12 of adipogenic induction. RPL13A was used for normalization. Data 
were shown as means ± SEM (n = 3). *p < 0.05 vs. ctrl; #p < 0.05 vs DC-CM in presence of the isotype control by one-way ANOVA followed by Tukey’s Multiple 
Comparison Test.
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expression. As expected, the control peptide Arg-Gly-Glu (RGE) 
did not alter CCL5 production (Figure  5C). Taking together, 
these results suggest that, in resting conditions, OPN released by 
DCs induces CCL5 upregulation. CCL5 production highly dif-
fered between resting and inflammatory conditions. As shown in 
Figure 5D, in the presence of proinflammatory cytokines, high 
levels of CCL5 were detected in DCs, and even more in MSCs, cul-
tured alone. In DC/MSC coculture, CCL5 levels are conspicuous, 
though lower than those produced by MSCs alone and lower than 
the sum of the values for each cell type cultured separately.
interaction of cD1c+ Dcs and Mscs  
in human BM
CD1c+ cells in normal human BM are rare and display a 
round shape with no dendrites. CD1c+ cells may be interstitial 
FigUre 4 | DC-conditioned medium induces mesenchymal stromal cells (MSC) differentiation into osteoblasts through osteopontin release. (a) MSCs were 
cultured for 14 and 21 days in osteogenic differentiation medium in the presence of 30% DC-CM or RPMI (control condition, ctrl) and stained with Alizarin Red S to 
identify mineralized deposits. (B) Quantification of Alizarin Red staining via dissolving the dye and measurement of subsequent absorption at optical density of 
405 nm. *p < 0.05 vs. ctrl by Student’s t-test. (c) The mRNA levels of alkaline phosphatase, RUNX, and CCL5 were analyzed by real-time PCR at days 7 and 14  
of culture of MSC in presence of DC-CM or rhOPN. RPL13A was used for normalization. Data were shown as means ± SEM (n = 3). *p < 0.05 vs. ctrl by Student’s 
t-test.
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(Figures  6A,B) or perivascular (Figure  6C) and, as shown by 
double immunostaining, they do interact with CD271+ MSCs. 
This observation confirms what originally suggested by Dokić 
et al. (23) in a different setting and fully supports our hypothesis.
When evaluating OPN expression in normal human bone 
marrow biopsies (BMB), we found granular positivity in the cyto-
plasm of megakaryocytes, a distinctive Golgian-dot expression 
in the cytoplasm of cells lining small capillaries and in scattered 
interstitial cells (Figure  6C). No evidence of interstitial OPN, 
previously described in plasma cell neoplasms (49), was detected 
in normal BMB.
By double immunostaining, OPN+ cells were negative 
for Myeloperoxidase and E-cadherin, excluding respectively 
myeloid and erythroid precursors; CD14+ monocytes were also 
negative (not shown). The large majority of OPN+ cells were 
CD38+ plasma cells, lined up in perivascular spaces, suggesting 
that such expression is constitutive in reactive plasma cells and 
not exclusive of pathological plasma cell proliferations (49) 
(Figure 6D). When immunostaining normal BMB with CD1c 
and OPN, only weak OPN expression was observed in proximity 
of rare CD1c+ DC while in myelofibrotic BMB OPN+ DC could be 
clearly found in the contest of DC–MSC interaction (Figure 6E, 
inset). Notably, this difference may be explained by the strong 
increase of CD271+ stromal stem cells in this pathological condi-
tion (Figure 6E). Although these findings on human tissue need 
to be confirmed in a larger cohort, they support our in  vitro 
observations.
DiscUssiOn
Mesenchymal stromal cells are known to control immune cell 
functions and to regulate immune responses in both homeostatic 
and inflammatory conditions. Our results from in vitro studies 
show that OPN production in DC/MSC cocultures is regulated 
by the state of activation of MSCs and that OPN released by DCs 
can influence MSC differentiation. Moreover, we detected OPN 
FigUre 5 | Osteopontin (OPN) released by dendritic cells (DCs) modulates CCL5 production in DC/mesenchymal stromal cells (MSC) coculture. (a) DCs were 
cultured in the absence or in the presence of MSCs. Supernatants were harvested after 48 h and assayed by ELISA for CCL5 (left) and OPN (right) (mean ± SEM  
of four independent experiments). *p < 0.05 vs. DC alone by one-way ANOVA followed by Tukey’s Multiple Comparison Test. (B) MSC were incubated for 24 and 
48 h with different concentrations of DC conditioned medium (DC-CM) and CCL5 concentrations were measured in the supernatants by ELISA (mean ± SEM of four 
independent experiments). *p < 0.05 vs. MSC alone at 24 and 48 h, respectively by Student’s t-test. (c) DCs and MSCs were cocultured for 48 h in the presence or 
in the absence of the antagonistic integrin inhibitors RGD (10 µg/ml) and cilengitide (CIL) (2 µg/ml). RGE was used as a control peptide. CCL5 concentrations were 
tested by ELISA. Results are expressed as % of CCL5 production by DC/MSC set as 100% and are representative of four independent experiments. *p < 0.05 vs. 
DC/MSC coculture in presence of RGE by Student’s t-test. (D) DCs were cultured alone or with MSCs (ratio DC/MSC 5:1) in the absence or in the presence of the 
proinflammatory cytokines (IL-1β, TNF-α, IL-6) for 48 h and OPN levels was determined in the supernatants by ELISA (mean ± SEM of seven different experiments). 
#p < 0.05 vs. DCs alone in the absence of cytokines; *p < 0.05 vs. MSCs alone in the presence of cytokines by Student’s t-test.
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FigUre 6 | Interaction of CD1c + dendritic cells (DCs) and CD271 + mesenchymal stromal cells (MSCs) in human BM. (a–D) Normal BM. (a,B) Show the 
interaction of CD1c+ (brown) DCs with CD271/NGFR+ (red) MSCs in the interstitium of normal hematopoietic matrix, even near an adipocyte (#). (c) Shows this 
interaction next to a vessel (*) in the proximity of which osteopontin (OPN) (blu) is produced (arrows). Double immunostaining for CD38 (blue) and OPN (brown) 
showed that plasma cells are the major expressors of OPN in normal human BM (D). (e) BM with myelofibrosis: intertrabecular spaces show dense network of 
CD271+ MSCs (red) that interact with scattered CD1c+ DCs (brown, arrow heads); in this contest, OPN (blue) production can be detected [(e), inset].
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production in the contest of MSC-DC colocalization in tissue 
sections of human BM.
Dendritic cells are known to be an important source of OPN 
both in vitro and in vivo (28, 34), and this study shows that resting 
MSCs can further increase OPN production when cocultured 
with DCs. On the contrary, in the presence of proinflammatory 
cytokines, MSCs exert an opposite effect inhibiting OPN produc-
tion. Coculture experiments of MSCs and DCs performed with 
transwell inserts indicated that MSCs regulate OPN production 
both by the release of soluble factors and by a cell–cell contact 
mechanism. MSCs constitutively express adhesion molecules that 
are involved in the direct interaction between MSCs and immune 
cells (50). For example, CD58 and CD54 play an important role 
in MSC/T cells interaction (50). Similarly, CD44 and CD29 are 
involved in the contact of human hematopoietic progenitor cells 
and MSCs (51, 52). By the use of blocking monoclonal antibodies, 
it was possible to show that resting MSCs upregulate OPN pro-
duction by a cell–cell contact mechanism involving the adhesion 
molecule CD29; other membrane proteins, such as CD44, CD54, 
and CD58, were not apparently involved in OPN production. 
However, the partial reduction of OPN observed using anti-CD29 
indicates that other interactions likely contribute to this process.
Conversely, the inhibition of OPN production by activated 
MSCs was mediated by the release of soluble factors. PGE2 
released by MSCs was identified as the main soluble factor 
responsible for this inhibition. This conclusion is supported by 
multiple experimental approaches, including the use of IDM to 
block PGE2 production, the pharmacological blocking of the two 
main PGE2 receptors expressed by DCs, namely EP2 and EP4, and 
the increasing of intracellular concentration of cyclic AMP, the 
main second messenger downstream EP2/EP4 activation (53–55).
Although in the past few years, the attention was mostly 
focused on the ability of MSCs to regulate immune cells, such as 
DCs, it is conceivable that cell-to-cell communication is bidirec-
tional, with DCs also being able to influence MSC functions (56). 
The influence of immune cells on MSCs lineage commitment is 
an intriguingly field that has increasingly attracted great attention 
in recent years (19). In this line, lymphocytes were reported to 
inhibit MSC-driven bone regeneration through the secretion of 
IFN-γ and TNF-α (57). Similarly, mononuclear phagocytes were 
reported to drive osteogenic differentiation (58, 59). No evidence 
of a direct role of DCs in MSCs differentiation is so far available. 
To our knowledge, there is only a report by Pamir et  al. (60) 
indicating that under physiological conditions DCs play a role in 
adipose tissue homeostasis.
Here, we report that medium conditioned by resting DCs 
inhibits MSC differentiation to adipocytes by a mechanism 
that depends on the presence of OPN. The capacity of OPN to 
interfere with adipocyte development and functions is also sub-
stantiated by the findings that OPN deficiency in mice promotes 
adipogenesis (61).
While inhibiting adipogenesis, DC supernatant promoted 
MSC differentiation to osteoblasts, as revealed by the increased 
Alizarin Red S staining. This dual opposite regulation was paral-
leled by the dowregulation of genes involved in adipogenesis (e.g., 
ADIPOQ, FAB4, and PPARγ2) and in the upregulation of genes 
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involved in osteogenesis, such as ALP, RUNX2, and CCL5. In this 
regard, it is interesting to note that CCL5 and its receptor CCR1 
were shown to be required for osteogenesis of human MSCs 
(48, 62). In the cocultures MSC/DC, characterized by high levels 
of OPN, CCL5 expression was increased compared with DCs 
and MSCs alone, suggesting that OPN might contribute to CCL5 
induction. Indeed, our studies using supernatants from DCs 
and RGD peptide demonstrate that DC-derived OPN induces 
CCL5 production from MSCs. Thus, we propose that OPN 
might induce osteogenic differentiation through a direct effect 
and an amplification loop via CCL5. Interestingly, in line with 
our results, tumor-derived OPN has been shown to induce MSC 
expression of CCL5 to enhance tumor growth and metastasis 
(63). Altogether, these results support the existence in MSC–DC 
cocultures of a pro-osteogenic cytokine network orchestrated by 
the production of OPN by DCs.
An important question to be answered is where the interac-
tion between DCs and MSCs might take place. Localization 
studies identified MSCs in the perivascular regions of many 
tissues (healthy adipose tissue, BM niche, periapical lesion) and 
direct DC–MSC interaction was shown to happen in situ in peri-
apical lesions (23). In this study, we show for the first time the 
co-localization of CD1c+ DCs and CD271+ MSCs in human BM 
from control subjects and patients with myelofibrosis, a pathology 
characterized by high CD271 expression. As previously reported 
(64), human BM specimen demonstrated few (estimated 1% or 
less) CD1c+ DCs; however, double immunostaining revealed a 
remarkably intimate relationship between CD271+ MSCs and 
CD1c+ cells. In BM, the large majority of OPN+ cells were CD38+ 
plasma cells lining small capillaries spaces. By double immu-
nostaining with OPN and CD1c, OPN+ DCs were found in BM in 
the contest of DC–MSC interaction. Further studies are required 
to better elucidate the role of OPN in the interplay between DCs 
and MSCs in normal and pathological conditions.
Based on our data and on the data available in literature we 
propose two scenarios in which the opposite OPN regulation 
observed during the DC/MSC interplay might be relevant. The 
first one is at sites of inflammation where activated MSCs inhibit 
OPN production through the release of PGE2 and reduce the 
DC-driven proinflammatory processes. The second is the BM 
environment that contains resident MSCs in addition to various 
immune cell types, including DCs albeit in a low number (65, 66). 
Here, MSCs contribute to the homeostasis of the hematopoietic 
compartment and differentiate into osteoblasts, adipocytes and 
reticular cells according to local soluble factors [for review, see 
Ref. (31, 67, 68)]. Interestingly, OPN is a HSC niche component 
known to regulate the size of the hematopoietic stem cell pool 
(32, 67, 69, 70). We speculate that within this environment, 
the interplay between DCs and MSCs may contribute to the 
upregulation of OPN production with the consequent inhibition 
of MSC-derived adipogenesis and the induction of osteogenic 
differentiation (hypothetical model in Figure 7). Taking together, 
these results indicate that DC-derived OPN is finely regulated by 
MSCs and skew MSC differentiation.
eThics sTaTeMenT
This study was carried out in accordance with the recommenda-
tions of “Comitato Etico Interaziendale A.O.U. Città della Salute 
e della Scienza di Torino—A.O. Ordine Mauriziano—ASL TO1, 
number 0009806” with written informed consent from all sub-
jects. All subjects gave written informed consent in accordance 
FigUre 7 | Hypothetical model for osteopontin (OPN) production in dendritic cell (DC)/mesenchymal stromal cells (MSC) cross-talk. In the perivascular area of the 
hematopoietic niche, DC/MSC interaction results in upregulation of OPN and CCL5 that influences the balance between osteogenesis and adipogenesis of MSCs.
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